Reports and Briefs on Pharmaceuticals and Healthcare in Brazil

The following industries match your search criteria:

Published within

« | 1 | 2 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues

Examination of the key issues in the treatment of sexual dysfunction, including risk factors, estimates of patient potential, overview of current and pipeline treatments, unmet needs, analysis of commercial opportunities and key stakeholder opinions.

Published By Datamonitor
04 Mar 2010 $7600
Buy
Report
Report

Brazil Pharmaceutical Market Overview – Strong market growth continues, but regulatory risks increase

Overview of the pharmaceutical market in Brazil including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis, and pharmaceutical market and pharmaceutical company infrastructure analysis.

Published By Datamonitor
21 Sep 2012 $5700
Buy
Report
Report

Pharmaceutical Key Trends 2011: Socio-Demographic and Economic Overview

Analysis of socio-demographic and economic trends across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Published By Datamonitor
13 Apr 2011 $1900
Buy
Report
Report

Brazil Pharmaceutical Market Overview - Expanding healthcare access drives double-digit sales growth

Overview of the pharmaceutical market in Brazil including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
26 Aug 2010 $7600
Buy
Report
Report

Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

Datamonitor's survey of 300 respiratory experts in Brazil, India, China and the US addresses increased interest in COPD in the emerging markets. The US is included as a benchmark, providing unique insight and comparisons of COPD market dynamics.

Published By Datamonitor
22 Dec 2010 $15200
Buy
Report
Report

Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity

This report analyzes three emerging markets, Brazil, Russia and India as targets for HIV drug manufacturers. It discusses the commercial and regulatory environment, guidelines, domestic and multinational competition as well as market entry strategies.

Published By Datamonitor
25 May 2010 $3800
Buy
Report
Report

Pharmaceutical Key Trends 2010 - The patent cliff dominates but growth opportunities remain

An overview of key trends shaping the pharmaceutical industry today, as well as drivers and resistors that are set to play a central role in the future as companies look to increase sales and boost profitability.

Published By Datamonitor
17 Mar 2010 $11400
Buy
Report
Report

2009 Pharmaceutical M&A Overview

An overview of M&A trends for the top 150 global pharmaceutical companies during 2008 and 2009 with discussion of the drivers of recent deals, plus case study analysis of key M&As.

Published By Datamonitor
17 Dec 2009 $11400
Buy
Report
Report

Orphan Drug Trends

Datamonitor’s report Orphan Drug Trends provides an overview of orphan drug regulations in the major pharmaceutical markets, including pricing and reimbursement issues and an analysis of Big Pharma’s growing interest in orphan drugs.

Published By Datamonitor
25 Nov 2011 $5700
Buy

« | 1 | 2 | » »|

No help is available.